Trial intelligence / Profile preview

IV busulfan + cyclophosphamide (BuCy2) once-daily regimen in adults with AML in first complete remission undergoing hematopoietic stem cell transplantation

2009-016601-42Phase 2Completed

Sponsor: Pierre Fabre Laboratories
Start: Jan 2010
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of busulfan in acute myeloid leukemia (AML), sponsored by Pierre Fabre Laboratories. Primary endpoint: Primary busulfan exposure targeting. Started Jan 2010; status: completed.

Drugs

busulfan

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on 2009-016601-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-016601-42.